Industry
Pharmaceuticals
Topic
Investments
People
Find news about people
Organizations
Find news about organizations
Alumni
Find news on alumni of any org
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Investments in Pharmaceuticals
... CANADIAN DAILY STOCK REPORT RepliCel Life Sciences Inc. (TSXV:RP), Canada's 49th largest Biotechnology company by market cap, has climbed ...
... clear he expects new oncology drugs to fill the yawning revenue gap AbbVie will experience with the loss of Humira patent protection. The company is ...
... the deal. AGS plans to list on the NYSE as "AGS." [ts_bullet_primary] ARMO Biosciences , a Redwood City, Calif.-based immunotherapy developer, said it plans to ...
... medical grade cannabis from Cannbit through the Company's wholly owned subsidiary, Cannmart Inc. ("Cannmart"). The Company is pleased to have the opportunity to participate in ...
... its direction to blockchain technology. The Company is changing its name to Millennium Blockchain (www.mblockchain.io) and has brought on key executives to partner with current ...
... research to the investment community. Today we are offering reports on SPPI, TLGT, VRTX, and VVUS which can be accessed for free by signing up ...
... UK-based Redwood Technologies Group, a provider of communications technology and cloud contact center solutions, has ...
... YOFOTO (China) Health Industry Co. Ltd to Invest in Becoming RepliCel's Strategic Partner for Greater China Terms Include an Up-front Investment of USD ...
... Green Organic Dutchman Holdings Ltd. ("TGOD"), announced a strategic investment by Aurora Cannabis (TSX:ACB) as well as a supply contract. According to Aurora's news release ...
... definitive preferred stock and warrant Securities Purchase Agreement with its majority stockholder Mayne Pharma under which Mayne Pharma has agreed to invest up to $5 ...
... molecular basis of hearing loss, said Steven Holtzman, chief executive of Decibel Therapeutics Inc. in Boston. Decibel, founded in 2015, has raised almost $57 million ...
... Regeneron Pharmaceuticals has formed a pre-competitive consortium with AbbVie, Alnylam Pharmaceuticals, AstraZeneca, Biogen ...
... Braeburn Pharmaceuticals, Inc. (Braeburn) today announced that the Company has completed a $110 million ...
... VIOLATION OF U.S. SECURITIES LAW. APAC Resources Inc. ("APAC") (CSE:APG)(CSE:APG.CN)(CNSX:APG) and XORTX Pharma Corp. ("XORTX") are pleased to announce the completion of the previously announced ...
... there are two notable deals I want to put on your radar. Celgene agreed to acquire Impact Biomedicines, a San Diego, Calif.-based developer of cancer ...
... its first round of fundraising, is now an overnight unicorn. Pharmaceutical giant Celgene announced on Sunday plans to acquire the startup for $1.1 billion, a ...
... development for Alzheimer's and Parkinson's disease. ( WSJ ) 3. Generic drugmaker Perrigo Company tapped Uwe Rohrhoff as its new CEO. Rohrhoff, who was most ...
... David Michelson, M.D., who led the failed Alzheimer’s BACE inhibitor program, left Merck after 11 years to become CMO of Proclara Biosciences. FierceBiotech > Backed ...
... Cannabis company chief's miracle ...
... said Ping An Chief Innovation Officer Jonathan Larsen in a statement. INDICATIONS Allergan to cut jobs. Botox maker Allergan is sharpening the ax to lop ...
... reporting the total following the series A is nearing $1 billion. RELATED: Genentech lays $310 million wager on BioNTech’s mRNA cancer vaccine platform Some of ...
... today announced a $75 million Series B financing co-led by new investor Bristol-Myers Squibb and existing investor New Enterprise Associates (NEA). Other new and existing ...
... Oculis (http://www.oculis.com), a clinical-stage biotechnology company focused on the development of breakthrough non-invasive ...
... Genentech, a member of the Roche Group, Eli Lilly and Company, Sanofi, Genmab and Bayer Animal Health. Helmut Jeggle, Chairman of BioNTech, commented: "Our aim ...
Want to see the full history on Investments in Pharmaceuticals? Upgrade to RelSci Pro now!
Start My Free Trial